https://www.selleckchem.com/pr....oducts/nedometinib.h
008 and p .001, respectively). We estimated a significant increase in the total number of deaths (+12.0%) when moving from a 0-3-months to a 12-month delay (p= .005), and a significant change in mortality distribution by stage when comparing the baseline with the 12-months (p .001). Screening delays beyond 4-6 months would significantly increase advanced CRC cases, and also mortality if lasting beyond 12 months. Our data highlight the need to reorganize efforts against high-impact diseases such as CRC, considering
Like
Comment
Share
